The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of imatinib (IM) plus mFOLFOX-bevacizumab in patients with advanced colorectal cancer.
M. Michael
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Roche (U)
Research Funding - Novartis
P. Gibbs
No relevant relationships to disclose
L. R. Lipton
No relevant relationships to disclose
M. Jefford
No relevant relationships to disclose
A. Milner
No relevant relationships to disclose
M. Gouillou
No relevant relationships to disclose
A. Hatzimihalis
No relevant relationships to disclose
G. A. McArthur
Consultant or Advisory Role - Novartis (U)
J. R. Zalcberg
No relevant relationships to disclose